Abstract
Between 1981 and 1986, 126 patients with advanced stage, large cell lymphoma were treated with MACOP-B chemotherapy. Their six-year failure-free and overall survival is 52% and 62% respectively. Eighty-eight patients aged 60 or less had an excellent six year overall survival of 68%. The outcome for various subsets of patients is analysed according to the number of adverse prognostic factors including age, stage, lactic dehydrogenase level and number of extra nodal sites.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Humans
-
Leucovorin / administration & dosage
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Methotrexate / administration & dosage
-
Middle Aged
-
Prednisone / administration & dosage
-
Prognosis
-
Survival Rate
-
Vincristine / administration & dosage
Substances
-
Bleomycin
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Leucovorin
-
Prednisone
-
Methotrexate